RepliCel Life Sciences Inc.

Equities

REPCF

CA76027P4006

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 08:50:42 15/03/2024 pm IST			5-day change	1st Jan Change
0.0428 ^USD	+4.99%		-.--%	-4.89%

18/04	RepliCel Life Sciences Inc. Announces Secured Loan Agreement	CI
2023	RepliCel Life Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

RepliCel Life Sciences Inc. announced that it expects to receive CAD 0.116419 million in funding

January 17, 2023

RepliCel Life Sciences Inc. announced that it will receive CAD116,420 in funding on January 17, 2023. The company will issue common shares in the transaction. The company will issue securities pursuant to exemption provided under Regulation D.

Latest news about RepliCel Life Sciences Inc.

RepliCel Life Sciences Inc. Announces Secured Loan Agreement	18/04	CI
RepliCel Life Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	29/11	CI
RepliCel Life Sciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	24/23/24	CI
Replicel Life Sciences Inc. Announces That Peter Lowry Will Not Be Standing for Re-Election as A Director	31/23/31	CI
RepliCel Life Sciences Inc. Appoints Jamie Mackay to the Board of Directors	17/23/17	CI
RepliCel Life Sciences Inc. Announces Chief Financial Officer Changes	17/23/17	CI
RepliCel Life Sciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	31/23/31	CI
RepliCel Life Sciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	02/23/02	CI
RepliCel Life Sciences Inc. Auditor Raises 'Going Concern' Doubt	01/23/01	CI
RepliCel Life Sciences Inc. announced that it has received CAD 1.0131 million in funding	14/23/14	CI
RepliCel Life Sciences Inc. announced that it has received CAD 0.01225 million in funding	08/23/08	CI
RepliCel Life Sciences Inc. announced that it expects to receive CAD 0.01225 million in funding	02/23/02	CI
RepliCel Life Sciences Inc. announced that it expects to receive CAD 1.05 million in funding	26/23/26	CI
RepliCel Life Sciences Inc. announced that it has received CAD 0.116419 million in funding	26/23/26	CI
RepliCel Life Sciences Inc. announced that it expects to receive CAD 0.116419 million in funding	17/23/17	CI
RepliCel Life Sciences Inc. announced that it has received $0.558837 million in funding	06/23/06	CI
RepliCel Life Sciences Inc. announced that it has received CAD 0.841965 million in funding	03/23/03	CI
RepliCel Life Sciences Inc. announced that it expects to receive $0.558837 million in funding	30/22/30	CI
RepliCel Life Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	30/22/30	CI
RepliCel Life Sciences Inc. Announces Executive Changes	28/22/28	CI
RepliCel Life Sciences Inc. Announces Executive Changes	28/22/28	CI
RepliCel Life Sciences Inc. announced that it expects to receive CAD 0.8 million in funding	06/22/06	CI
RepliCel Life Sciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	30/22/30	CI
RepliCel Life Sciences Inc. Receives Test Results Showing That Cells Injected Through the DermaPrecise	02/22/02	CI
RepliCel Life Sciences Inc. Receives and Analyzes All Data and Images from Independent Laboratory Testing of the Dermaprecise Injector Prototype	26/22/26	CI

Chart RepliCel Life Sciences Inc.

Duration

Period

More charts

Company Profile

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Companyâs cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.

Sector

Biotechnology & Medical Research

Calendar

28/05/2024 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
REPLICEL LIFE SCIENCES INC.	-4.89%	2.78M
VERTEX PHARMACEUTICALS INCORPORATED	+2.93%	108B
ARGENX SE	+0.09%	23.46B
BIONTECH SE	-14.60%	21.72B
GENMAB A/S	-7.05%	18.64B
WUXI APPTEC CO., LTD.	-38.55%	17.45B
BEIGENE, LTD.	-8.83%	17.19B
NEUROCRINE BIOSCIENCES, INC.	+5.51%	13.99B
SAREPTA THERAPEUTICS, INC.	+37.49%	12.53B
VIKING THERAPEUTICS, INC.	+329.39%	8.81B

Bio Therapeutic Drugs